Return to homepagePandemic Pact

CORONA - SARS-CoV-2-VLP-IVD - Development of a certified in vitro diagnostic (IVD) for the reliable determination of COVID-19-specific immune responses in human serum; subproject 2: Design and production of virus-like particles (VLPs).

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 03COV01B

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $134,832.68

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)

  • Principal Investigator

    Axel Pruß

  • Research Location

    Germany

  • Lead Research Institution

    Charité - Universitätsmedizin Berlin

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Within the scope of the subproject, high-quality virus-like particles (VLPs) will be produced. For this purpose, a stable-transfected cell line will be developed. An innovative plasmid design strategy will be applied, which already contain relevant mutations of the virus (antigenicity). The special feature here is that the production design is set up in such a way that all steps (except for the one-time lentiviral transfection) do not require an increased safety level (everything below S1). Mass production is carried out at an external partner under the supervision of Dr. Stefan Hirschberg.